Welcome to our dedicated page for XORTX Therapeutics news (Ticker: $XRTX), a resource for investors and traders seeking the latest updates and insights on XORTX Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XORTX Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XORTX Therapeutics's position in the market.
Rhea-AI Summary
XORTX Therapeutics Inc. announces the amendment of 1,024,099 outstanding common share purchase warrants by changing the exercise price to USD $5.00 per share. The TSX Venture Exchange approved the amendments related to Private Placements from 2021 to 2022. Additionally, a new Warrant Acceleration Provision was introduced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. announces the publication of a research paper in the American Journal of Physiology-Renal Physiology focusing on the effects of increasing serum uric acid on Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study reveals that elevated uric acid levels can significantly impact cyst growth and kidney size in ADPKD, potentially accelerating disease progression. The research also highlights the potential benefits of XORTX's XORLO™ in attenuating these effects, offering new insights into the treatment of ADPKD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. welcomes Abigail Jenkins, a biotech industry veteran, to its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in delivering life-enhancing therapies. She has held key positions at various biopharmaceutical companies and holds a Master of Science in biotechnology. XORTX has granted 8,000 stock options to Ms. Jenkins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.85%
Tags
Rhea-AI Summary
XORTX Therapeutics Inc. announces participation in investor conferences, engagement of LHA Investor Relations for services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.85%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. announces the addition of Dr. Ronald Perrone to its Clinical Advisory Board, enhancing the expertise in treating autosomal dominant polycystic kidney disease (ADPKD). Dr. Perrone's vast experience in nephrology and clinical research will benefit the company's advanced clinical program, particularly the XRX-OXY-201 registration trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. reports significant progress in 2023, achieving key milestones in the development of therapies for kidney diseases. The Company received U.S. Orphan Drug Designation for the XRx-008 program for ADPKD, aligning endpoints for accelerated approval. XORTX made advancements in chemistry, manufacturing, and clinical studies, aiming to conduct a registration clinical trial in 2024. Notable achievements include FDA and EMA regulatory submissions, patent advancements, and organizational enhancements. The independent commercial assessment forecasts potential worldwide peak sales exceeding $1B annually for the XRx-008 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) announces the submission of a new patent for the treatment of chronic kidney disease, focusing on innovative therapies to treat progressive kidney disease. The patent outlines new formulations and methods for safer and more effective use of xanthine oxidase inhibitors (XOI) in the setting of CKD, including autosomal dominant polycystic kidney disease, diabetic nephropathy, IgA nephropathy, lupus nephritis, and focal segmental glomerulosclerosis. Positive topline results from the XRX-OXY-101 bridging pharmacokinetic clinical study reported substantial increases in the bioavailability of oxypurinol with the XORLO™ formulation platform, increased dose proportionality compared to non-formulated oxypurinol, and achieved therapeutic target values. These results will facilitate precise dosing recommendations for upcoming registration trials in individuals with progressing kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.18%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen. Mr. Treanor, a seasoned pharmaceutical industry executive, brings valuable experience to the Company. XORTX is preparing for the potentially pivotal Phase 3 study of XRx-008 in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) announces an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the Company to offer and sell common shares without par value with an aggregate offering price of up to US$3,701,931. The Company intends to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.74%
Tags
Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) has received a letter of compliance from Nasdaq regarding the minimum bid price requirement, leading to the curing of the deficiency. The company's common shares are now trading at or above US$1.00 per share for at least 10 consecutive trading days, resulting in the receipt of the compliance letter from Nasdaq. This development ensures that trading of the company's common shares on Nasdaq will continue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
XORTX Therapeutics Inc.
Nasdaq:XRTX
XRTX Rankings
XRTX Stock Data
7.68M
2.63M
4.08%
23.95%
0.73%
Support Activities for Nonmetallic Minerals (except Fuels) Mining
Mining, Quarrying, and Oil and Gas Extraction
United States of America
Calgary
About XRTX
xortx therapeutics inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. it has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. the company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. in addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. the company has a strategic alliance with teijin pharma limited to develop tmx-049, a xanthine oxidoreductase; and a partnership with the icahn school of medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with covid-19. xortx therapeutics inc. is headquartered in calgary, canada.